RANK and RANK Ligand Expression in Parotid Gland Carcinomas [PDF]
Applied Immunohistochemistry & Molecular Morphology, 2018 Recently, it has been reported that deregulation of the receptor activator of NFkB ligand (RANKL)/RANK signaling axis results in salivary gland tumor development in a mouse transgenic model.
Simoni, A +19 more
core +6 more sources
The role of RANK ligand/osteoprotegerin in rheumatoid arthritis [PDF]
Therapeutic Advances in Musculoskeletal Disease, 2012 In the complex system of bone remodeling, the receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) pathway is the coupling factor between bone formation and bone resorption. RANKL binds to the RANK receptor of pre-osteoclasts and mature osteoclasts and stimulates their activation and differentiation.
Piet Geusens
exaly +5 more sources
The role of rank-ligand inhibition in the treatment of postmenopausal osteoporosis
Reumatismo, 2011 Osteoporosis is a skeletal disease affecting millions of people worldwide in which a decreased bone mass and a microarchitectural deterioration compromise bone strength leading to bone fragility and increased susceptibility to fracture.
M. Varenna, D. Gatti
doaj +6 more sources
Genetic Polymorphisms of RANK, RANKL and their relation to osteoporosis (Polimorfismos genéticos de RANK y RANKL y su relación con la osteoporosis) [PDF]
, 2012 [eng] Osteoporosis is a systemic skeletal disorder and the most common metabolic bone disease. It is recognized as one of the most prevalent problems facing postmenopausal women in western society. The World Health Organization definition of osteoporosis
Yoskovitz, Guy
core +6 more sources
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
Clinical Interventions in Aging, 2012 Andrew J Yee, Noopur S RajeDivision of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USAAbstract: Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast ...
Yee AJ, Raje NS
doaj +1 more source
Rank ligand as a target in musculoskeletal neoplasms. [PDF]
Curr Rev Musculoskelet Med, 2015 Receptor activator of nuclear factor-κB ligand (RANKL) is a tumor necrosis factor (TNF) family member, which signals through the osteoclast surface RANK. As such, RANKL is required for osteoclast differentiation and function, namely bone resorption. There is now growing evidence that RANKL is a therapeutic target for musculoskeletal neoplasms, namely ...
Cote GM.
europepmc +4 more sources
Calibrated Weighted Rank Aggregation for Virtual Screening Independently Rediscovers Privileged Vitamin D Receptor Ligand Scaffolds. [PDF]
Comput Struct Biotechnol JComputational drug discovery relies on virtual screening to prioritize a small number of compounds for experimental testing, yet combining heterogeneous in silico scoring methods into a single robust ranking remains challenging.
Salimzhanov A +3 more
europepmc +2 more sources
Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature [PDF]
Endocrinology and Metabolism, 2022 Denosumab, which has been approved for the treatment of osteoporosis since 2010, is a fully humanised monoclonal antibody against a cytokine, receptor activator of nuclear factor kappa B ligand (RANKL), involved in bone resorption.
Wei Lin Tay, Donovan Tay
doaj +1 more source
Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis [PDF]
The Korean Journal of Internal Medicine, 2021 Background/Aims The present study aimed to investigate whether tocotrienol regulates interleukin 17 (IL-17)-induced osteoclastogenesis in rheumatoid arthritis (RA).
Kyoung-Woon Kim +6 more
doaj +1 more source
RANK Ligand Modulation of Autophagy in Oral Squamous Cell Carcinoma Tumor Cells [PDF]
Journal of Cellular Biochemistry, 2016 Sundaravadivel Balasubramanian +2 more
exaly +2 more sources